Please use this identifier to cite or link to this item:
Title: Any heart failure treatments associated with worsening renal function in patients admitted due to acute heart failure?
Authors: Limkunakul C.
Srisantithum B.
Lerdrattanasakulchai Y.
Laksomya T.
Jungpanich J.
Sawanyawisuth K.
Keywords: angiotensin receptor antagonist
antibiotic agent
beta adrenergic receptor blocking agent
brain natriuretic peptide
calcium channel blocking agent
contrast medium
dipeptidyl carboxypeptidase inhibitor
glyceryl trinitrate
inotropic agent
nonsteroid antiinflammatory agent
acute heart failure
chronic kidney failure
controlled study
creatinine blood level
diastolic blood pressure
disease exacerbation
heart ejection fraction
heart rate
hospital admission
human tissue
kidney function
major clinical study
observational study
oxygen saturation
priority journal
retrospective study
risk factor
sodium blood level
systolic blood pressure
Issue Date: 2021
Abstract: Background: Worsening renal function (WRF) occurs in approximately 25% of acute heart failure patients, and both baseline characteristics and heart failure treatment may increase the risk of WRF. This study aimed to evaluate additional risk factors for WRF in acute heart failure, particularly those related to heart failure treatment. Methods: This was a retrospective, observational, analytical study. The inclusion criteria were age 18 years or over, hospital admission due to acute heart failure, and having undergone at least two serum creatinine tests during admission. The eligible patients were classified into two groups: WRF and non-WRF. Predictors for WRF (including treatment parameters) were determined using logistic regression analysis. Results: During the study period, there were 301 eligible patients who met the study criteria. Of those, 82 (27.24%) had WRF. There were two independent factors associated with WRF occurrence: baseline diastolic blood pressure and beta blocker treatment, with adjusted odds ratios (95% confidence interval) of 1.060 (1.008, 1.114) and 0.064 (0.006, 0.634), respectively. The Hosmer-Lemeshow Chi square for the final model was 6.11 (p =.634).   Conclusions: After examining several heart failure treatments and baseline factors, we found that beta blocker treatment results improvement in kidney function. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
ISSN: 0886022X
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.